Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.64 |
| ▸ | TPMT | P51580 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7376309 | 0.94 | GSK3B (0.68) | GSK3BPTPN1TPMTCA1CA2 | |
| SCHEMBL205280 | 0.87 | GSK3B (0.80) | GSK3BPTPN1 | |
| SCHEMBL689331 | 0.80 | GSK3B (0.83) | GSK3BPTPN1 | |
| SCHEMBL28594745 | 0.80 | GSK3B (0.70) | GSK3BPTPN1 | |
| SCHEMBL11695106 | 0.78 | GSK3B (0.64) | GSK3BPTPN1TPMTCA1CA2 | |
| SCHEMBL247615 | 0.78 | GSK3B (0.70) | GSK3BPTPN1CA1CA2 | |
| SCHEMBL9909658 | 0.78 | GSK3B (0.67) | GSK3BPTPN1 | |
| SCHEMBL70930 | 0.78 | GSK3B (1.00) | GSK3BPTPN1CA1CA2 | |
| SCHEMBL79354 | 0.78 | PTPN1 (1.00) | GSK3BPTPN1 | |
| SCHEMBL3341123 | 0.78 | TPMT (0.54) | GSK3BPTPN1TPMTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118930487-A | 1,3, 5-Trisubstituted pyrazole compound and preparation method thereof | 赣南师范大学 | 2024-11-12 | — | — | CN | claimed |
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| CN-118930487-A | 1,3, 5-Trisubstituted pyrazole compound and preparation method thereof | 赣南师范大学 | 2024-11-12 | — | — | CN | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| CN-114539040-B | Method for synthesizing alpha-halogenated ketone compound by photocatalysis | 苏州大学张家港工业技术研究院 | 2023-06-23 | — | — | CN | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| CN-114539040-A | Method for synthesizing alpha-haloketone compound by photocatalysis | 苏州大学张家港工业技术研究院 | 2022-05-27 | — | — | CN | disclosed |
| US-20210346388-A1 | CDC7-Inhibiting Purine Derivatives and their use for the Treatment of Neurological Conditions | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2021-11-11 | — | — | US | disclosed |
| CN-107625766-B | Application of thiazole compound as antibacterial synergist | 上海医药工业研究院 | 2021-08-31 | — | — | CN | disclosed |
| EP-1292593-A2 | 2-(3,5-DISUBSTITUTED-4-PYRIDYL)-4-(THIENYL, THIAZOLYL OR ARYLPHENYL)-1,3-OXAZOLINE COMPOUNDS | Dow AgroSciences LLC (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020019425-A1 | p53 Inhibitors and therapeutic use of the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2002-02-14 | — | — | US | disclosed |
| US-20020006941-A1 | p53 inhibitors and therapeutic use of the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2002-01-17 | — | — | US | disclosed |
| WO-2001098296-A2 | 2-(3,5-DISUBSTITUTED-4-PYRIDYL)-4-(THIENYL, THIAZOLYL OR ARYLPHENYL)-1,3-OXAZOLINE COMPOUNDS | DOW AGROSCIENCES LLC (US) | 2001-12-27 | — | — | WO | disclosed |
| US-5962460-A | CONTROLLING CANCER GROWTH | NATIONAL SCIENCE COUNCIL (TAIWAN) (TW) | 1999-10-05 | — | — | US | disclosed |
| US-5646164-A | FOR THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASE | NATIONAL SCIENCE COUNCIL (TW) | 1997-07-08 | — | — | US | disclosed |
| EP-0379145-B1 | Substituted quinolinecarboxylic acids | AMERICAN CYANAMID CO (US) | 1997-05-07 | — | — | EP | disclosed |
| US-4968702-A | ANTIARTHRITIC, INHIBITORS OF PROGRESSIVE JOINT DETERIORATION, IMMUNOSUPPRESSANT | AMERICAN CYANAMID COMPANY (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0379145-A2 | Substituted quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-25 | — | — | EP | disclosed |
| US-3965181-A | Tricyclic pharmacological agents, intermediates and methods of making | SYNTEX (U.S.A.) INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | GSK3B 890/4885PTPN1 1527/4885TPMT 1148/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | GSK3B 890/4885PTPN1 1527/4885TPMT 1148/4885 |
| US-20020006941-A1 | p53 inhibitors and therapeutic use of the same | TP53, TP53BP1, CDKN1A | GSK3B 1792/4885PTPN1 659/4885TPMT 798/4885 |
| US-20210346388-A1 | CDC7-Inhibiting Purine Derivatives and their use for the Treatment of Neurological Conditions | CDC7, TARDBP, TDP1 | GSK3B 117/4885PTPN1 4307/4885TPMT 107/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | GSK3B 890/4885PTPN1 1527/4885TPMT 1148/4885 |
| US-20020019425-A1 | p53 Inhibitors and therapeutic use of the same | TP53, TP53BP1, CDKN1A | GSK3B 1792/4885PTPN1 659/4885TPMT 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.